Reading time:3 minutes, 11 seconds
This report functions as a potential basis for the diagnosis of narcolepsy and its pharmacological treatment. The report mainly focuses on the market status, patient types and product/service offerings. The healthcare market is constantly evolving to meet the needs of people who must remain immobile. The word “stay” can be defined in an almost unlimited number of ways. While many physicians and healthcare professionals consult reports to make critical business decisions, some still rely on their unique knowledge and resources to make these kinds of decisions on their own.
Click on the tab below to benefit from the sample copy of the report
Definition of Narcolepsy
Narcolepsy is a neurological condition in which patients experience uncontrollable sleepiness when falling asleep anywhere and anytime, even during the day. It is estimated that 9 out of 10 people with this disorder lose sense of their usual time and space. For some people, narcolepsy is a disorder of excessive daytime sleepiness, where the patient suffers from intense sleep episodes that can last from seconds to minutes. Narcolepsy is classified as cataplexy, which occurs while awake. Cataplexy is characterized by sudden weakness of an arm or leg after an emotional trigger such as laughter or anger. This diagram illustrates the same condition described in the title sentence of the blog (except for babies instead of “migraine” at the end)
Incidence and prevalence of narcolepsy
One and a half million Americans live with narcolepsy, so it’s essential to know the latest statistics on how many people have been treated. From 2005 to 2013, new diagnoses increased slightly, as evidenced by an increase in the diagnosis rate from 1.9% to 2.1%. A similar trend can be seen when considering new prescriptions; however, there was a drop in 2013 from 7.2 million to 6.6 million due to fewer treatments needed.
The value of the US market, which treats Narcolepsy disorder annually, will reach $1.6 billion by 2023. According to research and analysis conducted by IBISWorld, the report also certifies that the annual revenue of this trouble has maintained an average growth of 27% over the past three years.
Existing treatment options
The majority of existing narcolepsy treatments aim to relieve symptoms related to excessive daytime sleepiness. Novartis has secured billion-dollar effectiveness advice, with vital comparative data and clinical effects. Tesi Vohm, another on the market, is offered in 26 countries, including Germany and Japan. Another treatment option is Modafinil, which was synthesized from Adderall to increase arousal in patients. It was named “Drug of the Year” by the Military Chemical Weapons Guild in 2012
Investigating a New Treatment Option Discovered in a Clinical Trial: Focal Decompression Therapy
A recent clinical trial investigated focal decompression therapy. While the treatment option was found to be safe and effective, some results left participants at odds over whether or not it was an effective treatment option for narcolepsy.
Click on the tab below for the instant purchase of the report with a flat rate discount of $500
Instant Buy Request
Product launches in the next 10 years
Narcolepsy drug launches, usually for a specific indication, have increased from just 1 in 1996 to 12 in 2018. As a result, the number of narcolepsy diagnoses is also increasing. In 2015, the estimated prevalence of narcolepsy was 0.1 in 10,000 people. By 2020, the estimate is expected to be 0.6 per 10,000.
The most critical intervention in 2018 will be the activation of narcolepsy treatment markets
It’s not a new area, but it seems like no one has influenced the market for a long time. We hope that our Business Intelligence Report can raise awareness among the general public and reduce misunderstandings and misconceptions around this type of market.